Zydus Lifesciences completes acquisition of Assertio
Business 16 Jun, 2026

Zydus Lifesciences completes acquisition of Assertio

Business To Business, New Delhi, 16th June, 2026:   Zydus Lifesciences on Tuesday announced the completion of its USD 166.4 million acquisition of US pharmaceutical company Assertio Holdings Inc., marking another significant step in the Indian drugmaker's expansion in the United States.
According to a regulatory filing, the acquisition was completed through Zara Merger Sub Inc, which successfully concluded a cash tender offer for all outstanding common shares of Assertio.

  • Assertio has become a wholly-owned subsidiary of Zydus Lifesciences.
  • All outstanding shares were acquired through the tender offer process.
  • Assertio's common stock has been delisted from the Nasdaq Global Market.
  • The company will no longer trade as a publicly listed entity.
The acquisition strengthens Zydus' presence in the world's largest pharmaceutical market, United States, and is expected to provide:
  • Access to Assertio's commercial portfolio.
  • Expanded market reach in specialty pharmaceuticals.
  • Additional revenue streams.
  • Greater scale in the US healthcare sector.
Assertio Holdings Inc. is a US-based pharmaceutical company focused on commercializing products in specialized therapeutic areas. The acquisition gives Zydus access to an established commercial platform in the US market.The transaction reflects a broader trend of Indian pharmaceutical companies expanding globally through acquisitions, partnerships, and investments in developed markets. Such deals help companies:
  • Strengthen their product portfolios.
  • Enhance distribution capabilities.
  • Gain access to new technologies and markets.
  • Diversify revenue sources beyond India.
For Zydus Lifesciences, the completion of the Assertio acquisition represents a significant milestone in its international growth strategy and reinforces its position in the global pharmaceutical industry.

Related News